Molecules
September 23, 2026
Aylín R. Tabal-Robles, María Eva González-Trujano, Gabriel Fernando Moreno-Pérez et al.
The genus Psilocybe has been characterized by central nervous system (CNS) effects and as a source of therapeutic drugs such as the alkaloids psilocybin and psilocin—secondary metabolites that produce rapid anxiolytic and antidepressant effects in preclinical and clinical studies. Furthermore, these mushrooms also contain bioactive primary metabolites, for example, the interesting case of...
npj Mental Health Research
September 22, 2026
Jack D. C. Dahan, David Dadiomov, Tijmen Bostoen et al.
This response addresses methodological concerns raised regarding our meta-analysis of subjective effects and therapeutic outcomes following ketamine and psilocybin treatment. We discuss the potential influence of psychotherapy and differences in subjective-effect questionnaires across studies, acknowledging these as important limitations. We argue that these factors may partly explain observed...
Expert Opinion on Therapeutic Targets
September 21, 2026
Sixtine Fleury, Katherine M. Nautiyal
INTRODUCTION: Depressive and anxiety disorders impose a substantial public health burden, yet current serotonergic therapies are limited by delayed onset, modest remission rates, and adverse side effects. Here we put forward the serotonin 1B receptor (5-HT1BR) as an important therapeutic target for mood related pathology. AREAS COVERED: We synthesize converging evidence from human and...
European Neuropsychopharmacology
September 19, 2026
Maia Mallevays, Lucie Berkovitch
Classic psychedelics, including lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT), have re-emerged as promising treatments for psychiatric conditions linked to suicidality. However, rare reports of increased suicidality potentially associated with psychedelic use have raised safety concerns. This article examines the complex relationship between psychedelics and...
Quality in Sport
September 17, 2026
Maciej Krzysztof Kisielewski, Natalia Fidut, Jakub Skrzypek et al.
Introduction and objective: Major depressive disorder (MDD) is a heterogeneous psychiatric condition characterized by affective, cognitive and somatic symptoms that considerably impair daily functioning. It is defined clinically by prolonged low mood, diminished interest or pleasure, and a range of associated disturbances, including changes in cognitive skills, appetite, and sleep patterns....
npj Mental Health Research
September 17, 2026
U. Lueken, Isabel Dziobek, Martha N. Havenith et al.
High ventilation breathwork (HVB) can induce altered states of consciousness with phenomenological similarities to those reported following administration of serotonergic psychedelics such as lysergic acid diethylamide (LSD), psilocybin or ayahuasca. Non-pharmacological methods capable of reliably eliciting such states may provide scalable models for investigating therapeutic mechanisms...
Revista JRG de Estudos Acadêmicos
September 16, 2026
Monique Vieira de Moura, Heder Albuquerque Azevedo Rocha, Márcio José de Carvalho Lima et al.
A depressão resistente ao tratamento (DRT) representa uma condição de elevada carga clínica e funcional, usualmente definida pela resposta inadequada a pelo menos dois tratamentos antidepressivos adequados. O interesse por psicodélicos clássicos ressurgiu diante da possibilidade de efeitos antidepressivos rápidos após uma ou poucas administrações em contexto supervisionado. O objetivo desta...
Psychotropes
September 15, 2026
Vincent Verroust
Cet article examine, dans une perspective d’histoire des sciences et d’épistémologie, les conséquences intellectuelles de la redécouverte des champignons hallucinogènes du Mexique par le mycologue Roger Heim dans les années 1950. Il montre que la prise en compte de leurs usages divinatoires chez les Mazatèques, l’attention portée aux effets psychiques de la psilocybine et les...
Applied Drug Research Clinical Trials and Regulatory Affairs
September 14, 2026
A S Shikha, Jignesh Shah, Darshil B. Shah et al.
Introduction: Psychedelic-assisted therapy has resurfaced as a promising intervention for treatment-resistant psychiatric disorders. However, regulatory pathways differ considerably across countries because of social, ethical, legal, and political factors. Methods: This review was conducted using the regulatory frameworks of Australia, Brazil, and the USA, along with publicly accessible data,...
Psychedelic Medicine
September 14, 2026
Vasileios Chytas, Georgios Tsimploulis, Dimitrios Chytas
Purpose: Ketamine and classic psychedelics have recently gained increased scientific interest regarding their role in pain management, while there is evidence that pain induces neural connectivity changes. We performed a scoping review to investigate the correlation of ketamine and classic psychedelics with pain-related neural connectivity, aiming to find potential therapeutic targets for these...